Among patients with oncogene-driven advanced NSCLC who were treated with TKIs, ctDNA clearance was associated with improved survival end points.

The first patient has been enrolled in the ARID II trial evaluating Voro Urologic Scaffold to improve continence after ...

Kathleen Coughlin is committed to removing obstacles for cancer patients, focusing on transportation, insurance, and ...

In a Phase 1b/2a trial for lymphoma and cytokine release syndrome, the first group's dose-limiting toxicity observation ...

CURE spoke with John Crispino, the director of the division of experimental hematology at St. Jude Children’s Research Hospital.

After a long battle with illness and seeking many specialists, I emphasize the need to self-advocate for ongoing care following my cancer diagnosis.

In a Q&A, Dr. Nataliya Uboha discussed how difficulty swallowing may signal esophageal cancer, treatment options and ongoing ...

The FDA granted breakthrough therapy designation to an autologous CAR-T cell therapy for pediatric patients with diffuse ...

A push for answers led to a rare blood disorder diagnosis after Joy’s symptoms were initially dismissed.

CURE provides access to the cancer news, latest oncology research & expert insights that serve as a guide to every stage of ...

Optune Lua received a CE Mark for metastatic non–small cell lung cancer with immune checkpoint inhibitors or docetaxel.

As spring arrives, I embrace the season’s renewal, reflecting on my journey with cancer and the freedom I’ll feel when I stop ...